•  
  • 中华人民共和国国家卫生健康委员会 主管
  • 中国医学科学院 主办
杂志信息/Information
  • 刊名:癌症进展
  • Oncology Progress Journal
  • 主管:国家卫生健康委员会
  • 主办:中国医学科学院
  • 社长:袁钟
  • 主编:赵平
  • 编辑部主任:骆春瑶
  • 编辑部副主任:陈闻
  • 编辑出版:中国协和医科大学出版社
    《癌症进展》编辑部
    100730,北京东单三条9号
    电话:(010) 65264353
    E-mail:azjzzz@163.com
    http://www.aizhengjinzhan.com
  • 市场运营:惠生文化传媒(北京)有限公司
    李长松 沈杰
  • 印刷:北京联合互通彩色印刷有限公司
  • 国内统一连续出版物号:CN 11-4971/R
  • 国际标准连续出版物号ISSN 1672-1535
  • 广告许可证:京东工商广字第0342号
下载专区/Download
订阅电子期刊/Subscribe

提交您的邮箱地址,我们会定期将电子期刊 发送到您的邮箱

期刊检索/Journal Search
扫一扫,关注

过刊目录

2017 年第 2 期 第 15 卷

多西他赛联合替吉奥对比多西他赛单药二线冶疗晚期非小细胞肺癌临床观察

作者:

单位:

关键词:二线治疗晚期非小细胞肺癌多西他赛替吉奥

  • 摘要:
  • 【摘要】目的:探讨多西他赛联合替吉奥对比多西他赛单药二线冶疗晚期非小细胞肺癌临床疗效。方法:收集我院2012年2月至2014年6月收治的经一线治疗后进展的晚期非小细胞肺癌患者100例,随机分为试验组和对照组,各50例,试验组给予多西他赛(60mg/m2,静滴一小时,第一天)联合替吉奥(40mg/m2,早晚饭后各服1次,连服14天),每三周重复;对照组行多西他赛单药治疗(75mg/m2,静滴一小时,第一天,每三周重复),所有患者随访至疾病进展或死亡。对比两组临床疗效、生存情况及毒副反应。结果:试验组客观缓解率、疾病控制率、无进展生存期、总生存期均显著高于对照组,差异具统计学意义(P<0.05);两组不良反应比较无统计学差异(P>0.05)。结论:多西他赛联合替吉奥二线治疗晚期肺小细胞肺癌的临床效果优于多西他赛单药治疗。
  • To evaluate the efficacy and toxicities of docetaxel plus S-1 compared with the single-agent docetaxel as second-line treatment of advanced non-small cell lung cancer(NSCLC). Methods: A total of 100 patients with stage III or IV NSCLC who had failed first-line platinum-based therapies were enrolled.They were randomly divided into two groups.The test group received infusion docetaxel(60mg/m2 on day 1 of every 21 days)plus oral S-1(40mg/m2 on day 1-14 of every 21 days);while the control group received docetaxel (75mg/m2 on day 1 of every 21 days)alone.All cases were followed up till progression or death. Results: The objective response rate,disease control rate,progression-free survival time and overall survival time were all significantly higher (P<0.05)in the test group than that in the control group.. There was no statistically significant difference in the side effects between the two groups.(P>0.05).Conclusion:Docetaxel plus S-1 had better efficacy and a similar adverse events rate in advanced non-small cell lung cancer as compared to the single-agent docetaxel, thereby making it an effective second-line therapy option for advanced NSCLC.